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Introduction: Low survival outcomes have been reported for the treatment of locally advanced non small cell lung
cancer (LA-NSCLC) with the standard of care treatment of concurrent chemoradiation (cCRT). We present our
experience of dose escalation using stereotactic body radiosurgery (SBRT) following conventional cCRT for patients
with LA-NSCLC.
Methods: Sixteen patients with a median age of 67.5 treated with fractionated SBRT from 2010 to 2012 were
retrospectively analyzed. Nine (56%) of the patients had stage IIIB, 6 (38%) has stage IIIA, and 1 (6%) had recurrent
disease. Majority of the patients (63%) presented with N2 disease. All patients had a PET CT for treatment planning.
Patients received conventional cCRT to a median dose of 50.40 Gy (range 45–60) followed by an SBRT boost with
an average dose of 25 Gy (range 20–30) given over 5 fractions.
Results: With a median follow-up of 14 months (range, 1–14 months), 1-year overall survival (OS), progression free
survival (PFS), local control (LC), regional control (RC), and distant control (DC) rates were, 78%, 42%, 76%, 79%, and
71%, respectively. Median times to disease progression and regional failure were 10 months and 18 months,
respectively. On univariate analysis, advanced age and nodal status were worse prognostic factors of PFS (p < 0.05).
Four patients developed radiation pneumonitis and one developed hemoptysis. Treatment was interrupted in one
patient who required hospitalization due to arrhythmias and pneumonia.
Conclusion: Risk adaptive dose escalation with SBRT following external beam radiotherapy is possible and generally
tolerated treatment option for patients with LA-NSCLC.
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For patients with locally advanced lung cancer concur-
rent chemoradiation (cCRT) provides improved survival
and local control compared to sequential chemotherapy
and radiation but with higher toxicity [1,2]. In order to
improve the therapeutic ratio, newer radiosensitizing
chemotherapeutic agents were introduced [3]. However,
when survival and pattern of failure following cCRT for
locally advanced NSCLC with conventional and new
chemotherapy agents were compared, no change in sur-
vival or failure pattern was observed in a recent system* Correspondence: sanadkaram@yahoo.com
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reproduction in any medium, provided the orreview of the literature [3]. Of the 15 studies reviewed in
the analysis, only one study varied in its radiation ther-
apy technique and dosing leading to the conclusion that
local control cannot be reliably achieved with conven-
tional radiation dosing and techniques. Local control
also has an impact on distant metastases [4]. As most
local recurrences after cCRT for locally advanced
NSCLC occur in the area of high radiation dose within
the tumor [5], radiation dose escalation by 10 Gy to
maximal dose of 74 Gy has been shown to reduce local
recurrence rate 15% [6,7].
However, the recently presented RTOG 0617 trial,
comparing 74 Gy in 37 fractions with 60 Gy in 30 frac-
tions, did not show an OS benefit for the higher dose
[8]. This was a 2 × 2 factorial design study designed toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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taxel, with or without cetuximab, for Stage III NSCLC.
A planned interim analysis led to the closure of the high
dose arms since the predetermined futility threshold was
crossed, indicating a low likelihood of a survival benefit
to high dose RT as used in this trial with additional ac-
crual and follow up. Both standard and high dose RT
were delivered with standard fractionation (2 Gy per
fraction), resulting in longer overall treatment time for
the high dose arm [8]. This suggests that unless radiation
dose escalation can be safely delivered in clinical trials,
there will be little improvement in patient outcome.
The introduction of stereotactic body radiotherapy
(SBRT) provides a feasible technique of radiation which
effectively increased tumor dose while sparing normal
tissues. In early stages NSCLC, local control and survival
were comparable to surgery in patients with multiple
co-morbidities precluding surgery [9]. SBRT may allow
increased local control and survival for locally advanced
NSCLC as well by targeting the PET positive tumor and
grossly enlarged mediastinal lymph nodes to a high radi-
ation dose [9]. In this manuscript we review our experi-
ence using SBRT boost as a means for dose escalation
for patients with locally advanced NSCLC.
Methods
Eligibility
After approval by the Virginia Hospital Center institu-
tional review board was obtained, all patients with a
diagnosis of clinically staged primary IIIA-IV NSCLC or
recurrent stage IA/IB NSCLC (per the American Joint
Committee on Cancer staging manual, 7th edition)
treated between 2010 and 2012 with either definitive or
palliative intent radiotherapy at our institution were
identified. Patients who had received conventionally
fractionated IMRT followed by a hypofractionated radio-
therapy boost to residual disease were retrospectively
reviewed. All patients had a histologically confirmed
diagnosis of NSCLC, and all had available a history; a
physical examination; a Positron Emission Tomography
computed tomography (PET/CT) imaging of the chest,
abdomen, and pelvis; and brain magnetic resonance im-
aging (MRI). All patients were determined by thoracic
surgeons to be inoperable. Patients who had had prior
thoracic radiotherapy were excluded. Charts were
reviewed to determine patterns of disease failure, toxicity
(as defined by the Common Terminology Criteria for Ad-
verse Events, version 3.0), and outcome.
IMRT treatment planning
For simulation, each patient was placed in the treatment
position on a flat table to ensure reproducibility of setup
during treatment and an FDG-PET/CT scan was obtained.
In patients without contraindication, IV contrast was uti-lized to delineate major blood vessels. Target volume
definitions were made in accordance with the 1993
ICRU Report #62.
The gross tumor volume (GTV) was defined as the
primary tumor and clinically positive lymph nodes seen
on the planning CT or PET scan (SUV >3) and generally
drawn on lung windows. The clinical tumor volume
(CTV) was defined as the GTV expanded by a 0.5-
1.0 cm margin as appropriate. To form the planning
tumor volume (PTV), at least 1.0 cm was added in the
superior-inferior direction and 0.5 cm in the axial plane
with an additional setup margin of 0.5 cm. Thus, the
total PTV included the CTV plus a total margin of at
least 1.5 cm to the superior-inferior dimension and at
least 1.0 cm in the axial plane. Normal anatomy identi-
fied on each CT planning image included the right and
left lungs (separately), heart, skin, esophagus, and spinal
cord.
IMRT dosimetry
All plans were created using Eclipse utilizing beams of
[6-18] MV photons, taking into account the inhomogen-
eity of lung tissue. Normalization of the treatment plan
covered 95% of the PTV with the prescription dose such
that the minimum PTV dose did not fall below 95% of
the prescription. To ensure good coverage, ≥ 99% of the
PTV received ≥ 93% of the prescribed dose. No more
than 1 cm3 of tissue outside the PTV received ≥ 120% of
the prescribed dose. For critical structures, dosing guide-
lines from QUANTEC were followed [10].
Treatment delivery
Radiation therapy (RT) commenced on day 1 of chemo-
therapy. Patients were treated 5 days per week with rou-
tine position verification using KV imaging. On days
when chemotherapy was given concurrently with RT,
attempts were made to administer chemotherapy prior
to RT. Need for treatment breaks were minimized
through nutrition consults, pain control, and medical
management.
Fiducial placement
In preparation for the stereotactic radiosurgery boost to
residual disease, most patients received fiducial place-
ment for real time image guidance (Conventional gold
seeds, Best Medical International, Springfield, VA),
which were placed into adjacent soft tissue either
brochcoscopically, or percutaneously. One to four gold
fiducials 0.8–1 mm in diameter by 3–7 mm in length are
usually placed non-colinearly for best translational cor-
rection of the radiation beam pointing. To minimize fi-
ducial migration a 1–2 week period of time was allowed
before simulation was completed in order to decrease
procedural edema and permit fibrosis and fixation of
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minimization of time between IMRT and CyberKnife™
boost was ideally achieved in patients by placing the fidu-
cials sometime in the last two weeks of their IMRT treat-
ment, allowing them to be simulated near the end of
IMRT and beginning SRS within just a few days of the
conclusion of IMRT.
For lesions which were adjacent to, and do not move in-
dependent of the spine, spinal tracking which uses spine
bony landmarks (X-Sight Spine™) was utilized instead. Pre-
treatment digitally reconstructed radiographs (DRRs) were
generated from CT scans. Three-dimensional target dis-
placements and global rotations of spinal structures were
determined by comparing radiographs with DRRs. Trans-
lations and global rotations were aligned during patient
setup and corrected during treatment delivery.
Radiosurgery treatment planning
Planning for the radiosurgery boost began one to two
weeks after fiducial placement. A new fine cut (1.25
mm) CT was used for targeting and treatment planning.
The planning CT scans were done with IV contrast as
needed to allow better distinction between tumor and
adjacent vessels or atelectasis. The residual disease, com-
prising the primary tumor and involved nodes, was
outlined by a radiation oncologist and designated as
gross tumor volume (GTV). The target was generally
drawn using CT pulmonary windows. However, soft tis-
sue window with contrast was sometimes used to avoid
inclusion of adjacent vessels, atelectasis, or mediastinal
or chest wall structures within the GTV. This target in-
cluded only abnormal CT signal consistent with gross
tumor and/or nodal volume (i.e., the GTV and the clin-
ical target volume (CTV) were identical). The pre-
treatment PET/CT was fused on all patients in order to
assist in defining the GTV. Additional margin of 5 mm
was added to the GTV to constitute the PTV, but adjust-
ments were made by the treating physician based on
tumor location, proximity of critical structures, and
tumor motion during treatment.
Radiosurgery dosimetry
Three-dimensional non-coplanar beam arrangements
were custom designed for each case to deliver highly
conformal prescription dose distributions. Generally,
more beams were used for larger lesions. As such, pre-
scription lines covering the PTV were typically around
80% but ranging between 60-90% line rather than the
more traditional 95-100%. Higher isodoses (hotspots)
were manipulated to occur within the target and not in
adjacent normal tissue.
Treatment conformality was determined in all patient
using the new conformity index (NCI), which was calcu-
lated by the formula: Treatment Volume × Prescrip-tion Isodose Line/(Volume of Target Covered by Prescrip-
tion Isodose Line)2. The following critical structures were
contoured: Spinal Cord, esophagus, brachial plexus, heart,
trachea and proximal bronchial tree, proximal trachea,
whole lung, and skin. As a general rule, prescription doses
were dictated by tolerance of surrounding structures,
which were in accordance with the AAPM Task Group
101 [11]. In other words, risk adaptive radiotherapy was
used whereby selectively boosting of tumor volumes was
accomplished without violating normal tissue complica-
tion constraints using information from functional im-
aging. The boost was generally performed in one plan
encompassing all targets with the exception of one case
where mediastinal disease could not be encompassed by
one plan without exceeding tolerance of critical structures.
The mediastinal disease was therefore treated in a separate
boost plan from the primary lung tumor.
BED was calculated for the IMRT and SBRT portions
of the treatment using the formula BED = nd(1 + d/α/β),
where n is the number of fractions and d is the dose per
fraction, and using an α/β ratio of 10 for acute reacting
tissues such as lung. The cumulative BED was
established by combining the calculated BED of IMRT
and SBRT.
Radiosurgery treatment delivery and post-treatment
follow-up
Tumors were actively tracked in real time during treat-
ment using Synchrony™. For the treatments the patient
wore a tight-fitting elastic vest. Three beacons emitting
visible red light pulsed at 30 Hz were placed on this vest.
The beacon positions were monitored by a camera
mounted at the foot end of the patient couch. This cam-
era continuously recorded the position of the markers
during the patients’ respiration cycle. In parallel, a series
of X-ray images of the internal fiducials were taken with
the patient breathing freely. These images established
the position of the fiducials and thus the tumor at the
time of these images. The time-stamps of the beacon
data (as captured by the camera) and the location data
of the internal fiducials (as determined at the instant of
the X-ray images) were synchronized. From a series of
these images a correlation model between the external
and internal positions was established. Thus, using the
instantaneous information from the external beacon, the
position of the tumor at that instant was calculated.
Using this dynamic model, the robot was able to track
the tumor motion in real time while the radiation is be-
ing delivered. As treatment commences X-ray images
were taken, either before each therapeutic beam or less
frequently for systematic breathers, updating the model.
For follow-up, clinical examinations and imaging studies
were performed at 3-month intervals from the end of
the treatment. Given that SBRT-induced consolidation
Table 1 Patients characteristics
Age (median, range) (67.5, 52–90)
KPS (median, range) (90, 60–100)
Gender (Male, Female) (9,7) (44%, 56%)
Histology (Adenocarcinoma, Squamous,
NSCLC) (%)
(8, 3, 5) (50, 19, 31)
Clinical Stage (recurrent IA, IIIA, IIIB) (%) (1, 6, 9) (6, 38, 56)
N Stage (0, 1, 2, 3) (%) (4, 1, 10, 1) (25, 6, 63, 6)
Maximum Diameter in cm (mean, median, range) (5.2, 5.0, 2.4-9.5)
Volume in cc (mean, median, range) (74.2, 65.7, 4.9-170)
Abbreviations: KPS Karnofsky Performance Status, NSCLC Non Small Cell
Lung Cancer.
Table 2 Treatment characteristics
Mean, Median (Range)
Total Prescribed Dose (Gy) 76.4, 75.4 (65–90)
SBRT Prescription IDL (%) 80.8, 80.0 (70–92)
Number of Boost Fractions 5, 5, (5–5)
SBRT Dose per Fraction (Gy) 5, 5 (4–6)
Total Boost Dose 25, 25 (20–30)
Duration of SBRT Treatment 9, 7 (5–11)
Number of IMRT Fractions 27.6, 28, (25–30)
IMRT Dose per Fraction 1.87, 1.8 (1.8-2.0)
Total IMRT Dose 51.42, 50.40 (45–60)
Duration of IMRT treatment 41.5, 42 (35–49)
Duration between IMRT and SBRT 25, 20 (7–97)
Cumulative BED10 98.8, 97.0 (81.1-120)
Coverage 95.7, 96 (80–100)
NCI 1.53, 1.43 (1.23-2.10)
Chemotherapy (concurrent, sequential) (15, 1) (94%, 6%)
Abbreviations: IDL Isodose Line, BED Biologically Effective Dose, NCI New
Conformity Index, which is calculated by the formula: Treatment Volume ×
Prescription Isodose Line/(Volume of Target Covered by Prescription
Isodose Line)2.
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using post-treatment CT based RECIST criteria, PET
scan was obtained on all patients at follow-up. Residual
PET uptake and maximal SUVs were used to distinguish
fibrosis from residual disease [12,13].
Statistical analysis
Progression-free survival (PFS) was defined as the time
from the first day of SBRT treatment to local, regional,
or distant failure or last follow-up in living patients with-
out evidence of recurrence or progression. Local control
(LC), local failure, regional failure, and distant failures
were defined as previously described [14]. Briefly, local
failure was defined as disease persistence or recurrence
in the targeted gross tumor volume (primary tumor, in-
volved nodes). Regional failure was defined as presence
of nodal or intrathoracic disease outside of the targeted
gross tumor volume. Patients were censored at the time
of death. Overall survival (OS) was the time from SBRT
treatment until death or last follow-up. Interpretation of
available FDGPET/CT, and CT scans with correlative
clinical examinations were used to assess for response of
the treated lesion 3 months after SBRT. Log rank tests
and Cox regression models were used to evaluate the as-
sociation between clinical factors and each survival out-
come. The independent variables considered were stage
(recurrent, IIIA, IIIB), gender (male, female), BED (<100,
>100 Gy), chemotherapy (yes, no), nodal status (<N2,
≥N2), age in years, GTV in cubic centimeters, and SBRT
dose in Gy. Kaplan-Meier plots are presented for se-
lected significant factors. Acute toxicities examined in-
cluded fatigue, chest pain, shortness of breath, cough,
hemoptysis, wheezing, and esophagitis that occurred
during treatment or within the first two weeks following
the end of treatment. Radiation pneumonitis was exam-
ined as a subacute toxicity in all patients. Analyses were




A total of 16 patients with locally advanced NSCLC re-
ceived SBRT boost at our institution. Baseline patient
and disease characteristics are listed in Table 1. Median
patient age at the time of treatment was 67.5 (range 52–
90) for all patients, with 44% males and 56% females.
The median KPS was 90 (range 60–100) and the hist-
ology varied between squamous (19%), adenocarcinoma
(50%), and nonspecified NSCLC (31%). Six (38%) of the
patients had stage IIIA, 9 (56%) has stage IIIB, and 1
(6%) had recurrent disease that had initially presented
with stage I disease and treated with lobectomy but re-
curred with hilar and paratracheal node metastasis. Ma-
jority of the patients (63%) presented with N2 disease.The median tumor volume was approximately 66 cc
(range 4.9-170) with a median maximal diameter of
5 cm (range 2.4-9.5).
Treatment characteristics
Treatment characteristics are presented in Table 2. Pa-
tients received a median IMRT dose of 50.40 Gy (range
45–60) with a median fractionation regimen of 1.8 Gy
(range 1.8-2.0) in 28 fractions (range 25–30). SBRT
boost dose averaged 25 Gy (range 20–30) given over 5
fractions with a median dose of 5 Gy thus bringing the
total cumulative dose to a median of 75.4 Gy (range 65-
90 Gy). The cumulative BED10 ranged from 81–120 Gy
with a median value of 97 Gy. On average 96% of the
PTV was covered by the prescription isodose line (range
80-100%) and the median conformity index was 1.43
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treatment and was given over 5–11 days (median 7 days)
with the exception of the one patient that required
hospitalization after the second SBRT treatment where
the duration was extended for 30 days. The median
elapsed time between IMRT treatment and SBRT boost
treatment was 20 days but the range varied between ir-
radiation and 7 and 97. One patient had extended treat-
ment time due to development of arrhythmias at the
end of his IMRT requiring hospitalization while in an-
other fiducial migration outside the tumor and require-
ment of fiducial replacement were the delaying factors.
The majority (95%) of the patients received cCRT chemo-
therapy except for one patient who received chemother-
apy prior to radiation due to patient’s preference.
Clinical outcomes and prognostic factors
The median followup was 14 months (0–36). The actu-
arial 1-year overall survival (OS), progression free sur-
vival (PFS), local control (LC), regional control (RC),
and distant control (DC) rates were, 78%, 42%, 76%,
79%, and 71% (Table 3, Figure 1). At a median followup
of 14 months the survival outcomes were not changed
for OS, LC, but drop to 61.5%, 68%, and 32% for DC,
RC, and PFS, respectively. The median time to disease
progression was 10 months and median time for re-
gional failure, which was the most prevalent pattern of
failure, was 18 months. All other median times were not
reached. On univariate analysis, age > 70 was a statisti-
cally significant predictor for regional failure (p = 0.03)
whereas advanced age and nodal status with N ≥ 2 were
worse prognostic indicators for PFS (p < 0.05) (Figure 2).
No other correlates for other survival outcomes reached
statistical significance.
Toxicity
The most common acute toxicities were fatigue and dry
cough experienced by 56% [9] and 50% [8] of theTable 3 Percent actuarial survival outcomes and control
rates
Median Followup (range in months) 14 (1–36)
Local control at 1 year, at 14 months,
(failed/controlled)
76%, 76% (3/13)
Regional control at 1 year, at 14 months,
(failed/controlled)
79%, 68% (6/10)
Distant control at 1 year, at 14 months,
(failed/controlled)
71%, 61.5% (5/11)
PFS at 1 year, at 14 months (progression/no
progression)
42%, 32% (10/6)
Overall survival at 1 year, at 14 months
(dead/alive)
78%, 78%, (4/12)patients, respectively (Table 4). For the majority of the
cases both symptoms were self limited and resolved
within 6–8 weeks following termination of treatment. In
one patient with stage IIIA disease treated with concur-
rent IMRT followed by boost for a total cumulative dose
of 90 Gy, his cough dry cough progressed into he-
moptysis and pneumothorax requiring hospitalization
but without any treatment breaks. He remains without
evidence of disease at 11 month post-treatment. Other
less common acute toxicities that were encountered in-
cluded shortness of breath and grade 2 esophagitis in 3
patients (18%) and chest pain in 4 patients (25%)
(Table 4). One patient required a treatment break of
21 days for treatment of arrhythmias and pneumonia
that developed 2 days after the initiation of his boost
treatment (same patient as the one mentioned above
under treatment characteristics). A total of 4 (25%) pa-
tients including the one who reported hemoptysis devel-
oped grade 2 acute pneumonitis. All required steroid
administration and one of the patients required hospita-
lization. There were no higher grade toxicities or any
deaths resulting from the treatment.
Discussion
Low survival outcomes have been reported for the treat-
ment of locally advanced NSCLC with standard of care
treatment of cCRT with locoregional control rates of ap-
proximately 65% with standard fractionation to 63 Gy
[2]. Attempts to improve upon local disease control with
radiation dose escalation have been undertaken [6,15,16]
based on the radiobiologic principle that the larger the
fraction cell kill, the greater the probability of disease
control [17]. The RTOG 01–17 trial evaluated the feasi-
bility of dose escalation concurrent with carboplatin and
paclitaxel chemotherapy and identified a mean tolerated
dose of 74 Gy [7]. On the basis of this result, the RTOG
06–17 trial randomized patients to 60 Gy versus 74 Gy,
concurrent with platinum-based chemotherapy with or
without cetuximab. Unfortunately, this trial closed early
due to excess number of deaths on the high-dose arm in
a futility analysis [8]. As the majority of locally advanced
patients have larger-volume disease, it appears that the
ability to dose escalate using conventional techniques
concurrent with chemotherapy is hindered by the radio-
sensitive nature of the surrounding critical structures
such as healthy lung, spinal cord, esophagus, heart, and
brachial plexus [18]. Recent technological advances in
conformal dose delivery have improved local control and
complication rates. SBRT is particularly suitable for dose
escalation because the rapid radiotherapy dose fall off
with current image-guided radiotherapy technique. At a
distance of 1.4 cm from the tumor, radiation dose fell
rapidly from 174 Gy to 10 Gy [19].
Figure 1 Survival outcomes. A. Local control. B. Regional Control. C. Progression Free Survival. D. Overall Survival.
P=0.01
Figure 2 Progression free survival by nodal status.
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Table 4 Toxicity profile of patients treated by SBRT boost
Fatigue 9 (56%)
Cough 8 (50%)
Shortness of Breath 3 (18.8%)
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NSCLC patients undergoing cCRT to 50.4 Gy followed by
SBRT boost to the tumor and involved nodes to either
16 Gy in 2 fractions or 28 Gy in 2 fractions showed dosi-
metric feasibility with respect to normal tissue tolerance
[17]. Incorporation of positron emission tomography
(PET) in SBRT treatment planning has also helped im-
prove treatment accuracy, avoid marginal miss, and de-
crease treatment toxicity [20-22]. Dose escalation based
on pre-treatment PET positivity and risk adapted treat-
ment planning to maximally tolerated dose have resulted
in excellent tumor control rates and minimal toxicity [22].
Using post-treatment PET at 5–6 weeks post-treatment to
boost residual disease to higher dose has been successfully
reported [21,23]. A recent prospective single institution
study examined the safety and feasibility of using SBRT to
boost PET residual disease for patients with mostly locally
advanced NSCLC (31 out of 35 patients had stage III dis-
ease [21]. SBRT boost following cCRT was given in either
2 fractions of 10 Gy each or 3 fractions of 6.5 Gy each
based on tumor location with local control rate of ap-
proximately 83% at a median followup of 13 months and
4 patients with acute radiation pneumonitis [21].
At a similar median followup our results show a me-
dian local control of 76% using a median SBRT boost
dose of 25 Gy in 5 fractions also with acceptable toxicity.
Our results also show acceptable regional and distant
control rates. However, disease progression remains poor
in our series. This could be due to the fact that there
was no overlap between local, regional or distant con-
trol. Our sample size was underpowered to detect pre-
dictors of disease progression. However, advanced nodal
disease was found to be a worse prognostic factor for
progression in our series. This is consistent with pub-
lished literature demonstrating poor prognostic associ-
ation between mediastinal nodal involvement and
disease progression in patients with Stage IIIA disease
[24]. In our series age was also a worse prognostic out-
come of both regional control and progression free sur-
vival. This is consistent with the recent analysis of seven
RTOG trials that showed age to be an important pre-
dictor of loco-regional control and overall survival in pa-
tients with locally advanced lung cancer [25].Conclusion
Concurrent chemoradiation for locally advanced NSCLC
remains associated with poor survival and significant
toxicity. Our retrospective analysis shows that combin-
ation of cCRT to 50.4 Gy followed by SBRT boost to pri-
mary tumor and involved nodes using a risk adaptive
regimen are possible with generally tolerable toxicity.
Our data is limited by its retrospective nature, short
follow-up, small sample size and heterogeneity of the
patient population that are inherent in observational
studies. Some of our patients had poor follow-up, and
therefore disease recurrence may have been more com-
mon than reported. Clinical trials testing the role of
using SBRT boost after definitive cCRT for locally ad-
vanced NSCLC are being undertaken [26] and results
from these trials should provide a more authoritative an-
swer to guide the treatment of this challenging disease.
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